🇬🇧 English

Questions: Why is blood vital for the human organism and what is its availability around the world? What are the current and future solutions to address worldwide blood shortages?

Introduction to Blood

Blood is a specialized connective tissue and circulating fluid composed of plasma (about 55% of total blood volume) and formed elements (about 45%, representing the hematocrit):

• Erythrocytes (Red Blood Cells - RBCs): Biconcave, anucleated cells filled with hemoglobin (approx. 250 million molecules per cell) specialized in transporting oxygen ${\text{O}}_2$ from the lungs to tissues and carbon dioxide ${\text{CO}}_2$ back to the lungs.
• Leucocytes (White Blood Cells - WBCs): Granulocytes (neutrophils, eosinophils, basophils) and agranulocytes (monocytes/macrophages, lymphocytes) dedicated to innate and adaptive immune defense.
• Platelets (Thrombocytes): Anucleated fragments derived from megakaryocytes in the red bone marrow that initiate hemostasis and clot formation.

Blood is pumped by the heart through a closed cardiovascular loop to all organs, acting as an integrating tissue that distributes nutrients, removes metabolic waste products (urea, lactate), conveys hormonal signals, and maintains thermal and electrolytic homeostasis.

Because hematopoiesis (erythropoiesis in the bone marrow under the control of erythropoietin / EPO) takes time to produce and mature new red blood cells (erythrocyte lifespan is 100–120 days), transfusions are vital in case of severe hemorrhage, traumatic blood loss, or severe anemia.

---

Global Distribution & Blood Donation Disparities

• Prevalence of ABO Groups: Across the world, O+ is the most common blood type (predominating in the Americas and parts of Africa, representing between 30% and 75% of populations), while A+ is highly frequent in Europe and North America.
• Collection Gap: A profound disparity exists between high-income and low-income countries: developed nations collect significantly more units per capita (over a 500% higher collection rate in Germany, Greece, and Sweden compared to parts of the Middle East and developing countries).
• Target Populations & Clinical Uses:
  • In developed countries, blood transfusions primarily support an aging population (cardiovascular surgeries, cancer chemotherapy, and trauma management).
  • In developing countries, up to 65% of transfusions are administered to children under 5 years old (severe malaria-induced anemia, malnutrition) and women with pregnancy-related obstetric complications.
• Component Therapy (Apheresis): Rather than transfusing whole blood, modern transfusion medicine separates donated blood into individual therapeutic fractions: packed red blood cells (pRBCs), platelet concentrates, and fresh frozen plasma (FFP). This allows one donation to treat multiple patients according to their specific clinical needs.
• Donor Safety: Approximately 54 countries still rely heavily on family/replacement or paid donors for over 50% of their supply, whereas the WHO standard aims for 100% voluntary, non-remunerated regular donations.

---

Part 1: Blood Availability and Transfusion Logistics

1. Is the volume of donated blood constant over time?

No. Blood inventory exhibits continuous and unpredictable fluctuations. Seasonal shortages routinely occur during holiday periods and summer vacations. Conversely, acute surges in donation are triggered by catastrophic mass-casualty events (e.g., the Las Vegas shooting) or public emergency appeals (e.g., the Surgeon General appeal during the COVID-19 pandemic). Despite occasional surpluses, inventories of universal red cells (O-negative) frequently hover near critically low thresholds.

2. Which factors influence blood donation rates?

• Public awareness & emergency appeals: Broadcasted national appeals and media coverage of mass traumas temporarily maximize donor turnout.
• Civic altruism & donor eligibility: Perceptions of social duty, fear of needles, hemoglobin screening deferrals, and collection site accessibility.
• Perishability of blood products: Red blood cells can only be stored for up to 42 days, and platelets expire within 5 to 7 days, necessitating an uninterrupted flow of incoming donations.

3. Public campaigns and emotional appeals: Are they effective? Why?

Public campaigns relying on solidarity and civic responsibility are generally effective because they appeal to altruism and empower individuals by showing that their personal contribution directly saves lives. However, their impact is often short-lived: they produce sharp, temporary spikes in donations without necessarily converting first-time donors into habitual, year-round donors.

4. Targeted donor recruitment campaigns

Certain campaigns specifically target ethnic minority populations or communities originating from regions with specific endemic antigen patterns. For example, patients with sickle cell disease (predominantly of African descent) require frequent transfusions with extended phenotypical matching (e.g., Rh and Kell antigens, or the Duffy antigen system) to avoid alloimmunization. Recruiting donors with similar genetic backgrounds is essential to ensure safe, long-term transfusion compatibility.

5. Define the "blood transfusion continuum"

The blood transfusion continuum refers to the coordinated, end-to-end supply and safety chain comprising:

$$\text{Donor Recruitment}\to \text{Blood Collection}\to \text{Testing (ABO/Rh typing a,d infectious disease screening)}\to \text{Fractionation / Processing}\to \text{Cold-chain Storage}\to \text{Compatibility Testing (Cross-matching)}\to \text{Bedside Administration and Hemovigilance.}$$

6. Would you say that blood transfusion is a safe process? Discuss this point.

In modern healthcare systems, blood transfusion is exceptionally safe, but risks cannot be reduced to absolute zero:

• Measures ensuring safety: Rigorous nucleic acid testing (NAT) and serological testing for transmissible pathogens (HIV, Hepatitis B and C, Treponema pallidum), automated forward and reverse ABO/Rh typing, and bedside pre-transfusion identity checks.
• Residual risks: Human clerical error (leading to acute hemolytic ABO incompatibility), rare immunological adverse events (transfusion-related acute lung injury / TRALI, alloimmunization), and resource constraints in low-income nations where systematic screening remains incomplete.

7. Conclude whether voluntary blood donation is a sufficient solution to meet worldwide blood needs.

No, current blood donation systems are insufficient on a global scale. While high-income nations maintain relatively stable supply chains, developing countries suffer from chronic, severe shortages that contribute directly to maternal and pediatric mortality. Moreover, aging demographics in Western nations threaten to decrease the eligible donor pool while increasing transfusion demand.

Current and future alternative solutions include:

1. Patient Blood Management (PBM): Minimizing blood loss during surgery via autologous blood recovery (cell salvage) and pharmacological antifibrinolytics (tranexamic acid).
2. Enzymatic conversion of blood groups: Using bacterial glycosidases to cleave terminal sugars from A and B erythrocytes, converting them into universal "O-type" red cells.
3. In vitro lab-grown RBCs: Culturing hematopoietic stem cells or induced pluripotent stem cells (iPSCs) into functional erythrocytes.
4. Artificial oxygen carriers: Developing hemoglobin-based oxygen carriers (HBOCs) or synthetic perfluorocarbon emulsions.

---

Part 2: Immuno-hematology, Genetics, and Biochemistry of ABO Blood Groups

                Fucosyltransferase (FUT1 gene)
Precursor Chain ----------------------------> H Antigen (Substrate)
                                                      |
                 --------------------------------------------------------------
                 |                                                            |
                 | A-glycosyltransferase                                      | B-glycosyltransferase
                 | (GTA allele)                                               | (GTB allele)
                 v                                                            v
             A Antigen                                                    B Antigen
(Terminal: N-acetylgalactosamine)                                    (Terminal: D-galactose)

1. Explain the existence of the different blood types from a molecular point of view

Blood groups in the ABO system are defined by specific oligosaccharide antigens (agglutinogens) anchored to transmembrane proteins (such as glycophorins) and lipid molecules (sphingolipids) on the erythrocyte membrane:

• Group A: Carries the A antigen, characterized by a terminal N-acetylgalactosamine residue attached to a core carbohydrate structure known as the H antigen.
• Group B: Carries the B antigen, characterized by a terminal D-galactose residue linked to the H antigen.
• Group AB: Displays both A and B antigens simultaneously on the erythrocyte surface.
• Group O: Possesses neither A nor B antigens; only the unmodified H antigen is present.

2. What is hemagglutination and how does it occur?

Hemagglutination is the macroscopic clumping of erythrocytes caused by an antigen-antibody reaction.

• Circulating antibodies (agglutinins)—primarily pentameric IgM immunoglobulins that occur naturally in plasma against the antigens absent from one's own RBCs—possess multiple antigen-binding sites.
• When Anti-A antibodies bind to A-antigens on separate adjacent red blood cells, they form intermolecular cross-links (immune complexes), cross-linking the cells into visible aggregates.

3. Interpret the results of the blood typing presented in the table

Blood typing requires two cross-verifications:

• Forward typing (Beth-Vincent test): Testing the patient's RBCs with known Anti-A and Anti-B reagent sera to identify surface antigens.
• Reverse typing (Simonin test): Testing the patient's serum with known reagent A and B red blood cells to identify circulating antibodies.

Forward Typing: Anti-A Reagent	Forward Typing: Anti-B Reagent	Reverse Typing: Test A Cells	Reverse Typing: Test B Cells	Interpretation (Blood Group)
+ (agglutination)	0 (no agglutination)	0	+	Blood Group A
0	+	+	0	Blood Group B
+	+	0	0	Blood Group AB
0	0	+	+	Blood Group O

4. Explain the necessity of blood typing before a transfusion

If a recipient receives incompatible red blood cells (e.g., Group A blood transfused into a Group O individual), the recipient’s pre-existing plasma antibodies (Anti-A) will immediately bind to the donor's erythrocyte surface antigens. This triggers massive hemagglutination, activates the complement cascade, and causes severe intravascular hemolysis. The resulting destruction of red blood cells releases free hemoglobin, causing acute kidney injury, disseminated intravascular coagulation (DIC), systemic shock, and potentially death.

5. Explain the terms "universal donor" and "universal receiver"

• Universal Donor (Group O, specifically O-negative): Group O erythrocytes carry neither A nor B agglutinogens on their membrane. Consequently, recipient plasma containing Anti-A or Anti-B antibodies will not react against these transfused cells, making O-negative pRBCs the safest choice in acute trauma emergencies when patient blood typing cannot be completed in time.
• Universal Receiver (Group AB, specifically AB-positive): Individuals with blood type AB do not manufacture Anti-A or Anti-B antibodies in their plasma (otherwise their antibodies would destroy their own cells). Therefore, an AB individual can receive red blood cells of any ABO group (A, B, AB, or O) without antibody-mediated immune rejection.

6. Compare the genetic sequences of the different blood type determining alleles

The high percentage identities shown in your alignment table illustrate that all ABO alleles belong to the exact same gene locus (ABO gene on the long arm of chromosome 9, at 9q34):

Allele Pair	Sequence Identity (%)	Molecular & Functional Divergence
A / B	99.62%	The $I^A$ and $I^B$ alleles differ by only seven single-base nucleotide substitutions across their coding region, leading to 4 critical amino acid differences (residues 176, 235, 266, and 268) in the catalytic domain. These 4 substitutions alter the binding pocket specificity of the enzyme, determining whether it preferentially binds UDP-GalNAc (A allele) or UDP-Gal (B allele).
A / O	99.91%	The $O$ ($i$) allele is almost completely identical to the $A$ allele, but carries a single-nucleotide deletion of guanine at position 261 ($\mathrm{\Delta }\text{G261}$). This deletion causes a frameshift mutation, introducing a premature stop codon that results in a truncated, completely non-functional enzyme.
B / O	99.53%	Reflects the combined sequence divergence of the catalytic site polymorphisms found in B plus the nucleotide deletion ($\mathrm{\Delta }\text{G261}$) of the O allele.

7. Study the composition and biosynthesis of the different blood antigens

1. Formation of the H Substance (Foundation):
   • A precursor lipid/protein core chain is modified by an enzyme called $\alpha$-(1,2)-fucosyltransferase (encoded by the $H$ gene / FUT1 on chromosome 19).
   • This enzyme attaches an L-fucose monosaccharide to the terminal $\text{D-galactose}$ of the precursor chain, producing the H antigen.
2. Biosynthesis of A and B Antigens:
   • Allele A ($I^A$): Codes for $\alpha$-(1,3)-N-acetylgalactosaminyltransferase. This enzyme transfers an N-acetylgalactosamine (GalNAc) moiety from UDP-GalNAc onto the terminal galactose of the H antigen.
   • Allele B ($I^B$): Codes for $\alpha$-(1,3)-galactosyltransferase. This enzyme transfers a $\text{D-galactose}$ residue from UDP-Gal onto the H antigen.
   • Allele O ($i$): Lacks transferase activity due to the frameshift truncation. The H antigen remains unmodified on the red blood cell surface.

8. Explain the existence of different blood types from a genetic point of view

The inheritance of the ABO blood system is governed by allelic polymorphism and Mendelian genetics:

• The ABO locus possesses three common alleles: $I^A$, $I^B$, and $i$ (or O).
• Codominance: $I^A$ and $I^B$ are codominant. If an individual inherits both ($I^A{I}^B$), both functional transferases are synthesized, leading to the simultaneous presence of both A and B antigens (blood group AB).
• Complete Dominance over O: Both $I^A$ and $I^B$ are completely dominant over the recessive allele $i$. Because the $i$ allele produces an inactive enzyme, heterozygous genotypes ($I^{A}i$ and $I^{B}i$) express the A and B phenotypes, respectively. Blood group O requires homozygous inheritance ($ii$).

9. Synthesis: Answer to the overall question

Blood is a vital, non-substitutable tissue because it provides convective long-distance transport for oxygen, carbon dioxide, essential fuels, and regulatory signals across all organs in multicellular organisms, directly preventing cellular hypoxia and maintaining internal physiological homeostasis.

However, its global availability is severely constrained by socioeconomic disparities in donor recruitment, fragile cold chains, short storage shelf-lives, and strict immunological compatibility requirements governed by the genetics of ABO and Rh antigens.

To overcome recurrent blood shortages worldwide, modern healthcare is combining component fractionation, targeted community blood drives, and Patient Blood Management, while investing in future biotechnologies such as enzymatic conversion into universal O-type blood, synthetic hemoglobin carriers, and stem-cell-derived erythrocytes.

Genotypes

Alan

• Allan should have a genotype of A || B → [AB]
• Monica should have a genotype of A || O → [A]
• Rick should have a genotype of (A || B && O) → [A], [B], [AB] but NOT O (would require O type)

Biosynth of blood antigens

You need, to fix fluctose, lactose and more to the blood cell an enzyme. An enzyme H is needed to create substance H and stick it to the blood cell (and enzyme A/enzyme B to add the last part from allele A or B)

Blood type can depend on a gene while other genes are present: a or b can be here but no gene H make O

(Gene H is called Tut1)

So A & B are dominant over O unless enzyme H is not present (which is not a gene from O)

Blood substitutes - a posible solution?

Options :

• Milk by Tehodor Thomas : helped a woman saved her life
• Lot of saline solutions tried on frog, but frog can live withouth blood solution so not really helpfull
• Potasium + Soduim + Milk sollution ok for Heartbeat
• PFC : biologically inert materials that can dissolve about 50 times more oxygen. Accepted by FDA but not commercialized as too expenseive
• IA usage

Advantages :

• Faster and Better Oxygen Distribution see PFC
• Longer Shelf Life see above the conservation of blood
• Universal Compatibility again above last course
• Prevention of transmission of agents because not from anybody
• Jehovah’s Witness ok with their religion

Is it a solution to the blood shortage? Yes and no... Poorer countries can't make artificial celles either.